SUMMARY
Immunotherapy has changed the treatment landscape for many tumour types. In patients with prostate cancer, different types of immunotherapy such as cellular, dendritic cell, peptide, viral, antigen-loaded dendritic cell or antigen-presenting cell vaccines and checkpoint inhibitors have been tested in randomised phase III trials as a single agent or in combination with other treatment modalities. Only one specific antigen-loaded dendritic cell (sipuleucel-T) has shown some benefit in terms of overall survival in this patient population. Newer treatments, such as bi-specific T-cell engagers or chimeric antigen receptor T-cell therapy, are being tested in early clinical trials in different subsets of patients with prostate cancer. Monoclonal antibodies, linked to radioactive isotopes, have been successfully used in the diagnosis and treatment of prostate cancer and are mentioned briefly. This review focuses on the role of cellular-based immunotherapy in patients with prostate cancer.
(BELG J MED ONCOL 2024;18(4):152–9)
